Key takeaways
Peptides are becoming a foundational part of the DIY health movement, spurred on by the success of GLP-1s.
Influencers like Joe Rogan are driving interest in the use of peptides, many of which have not been rigorously studied for efficacy and safety.
RFK Jr. used Rogan’s podcast recently to announce that the FDA would reclassify certain peptides to make it easier for compounders to produce and sell them.
Influencers don’t get much more influential than Joe Rogan. With nearly 20 million Instagram followers and over 35 million subscribers across Spotify and YouTube, Rogan reaches one of the largest male audiences in media — roughly 80% of his listeners are men. When he discusses health products or experimental therapies, he reaches a massive audience and moves markets.
This reach helps explain why U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. chose Rogan’s podcast in late February to preview a potential shift in federal policy. During the conversation, Kennedy said the U.S. Food and Drug Administration was considering reclassifying 14 peptides it had previously placed in Category 2, moving them to Category 1 status. The change would allow compounding pharmacies to produce the peptides legally and dispense them to consumers if prescribed by a licensed physician. While the move does not mean the compounds would necessarily become FDA-approved drugs, it would allow them to be prescribed and compounded in a regulated medical setting rather than being pushed into an unregulated, potentially shadowy marketplace.
For the fast-growing medical peptide industry, the policy signal was significant. Over the past decade, peptide-based drugs have become one of the most commercially successful classes of medicines in modern pharmacology. That success has been driven largely by GLP-1 therapies such as semaglutide and tirzepatide, developed by Novo Nordisk and Eli Lilly. Originally introduced for diabetes treatment, the drugs have rapidly expanded into obesity care and are now reshaping expectations for metabolic medicine. Analysts widely project that the global GLP-1 category could exceed $100 billion annually before the end of the decade.
As pharmaceutical companies were building this blockbuster class of medicines, a parallel peptide marketplace was developing outside the traditional regulatory framework. Today, a broad network of online vendors, longevity clinics, telehealth providers and social-media influencers promotes experimental peptides for all manner of conditions, from anti-aging to muscle recovery, fat loss to injury repair, and cognitive performance.
Rogan has emerged as one of the most visible public advocates of these compounds. On several podcast episodes, he has discussed using BPC-157 (body protection compound 157), a synthetic peptide that proponents claim may promote healing in muscles, ligaments and tendons. It is part of the so-called “wolverine stack” of peptide treatments popular among some of his listeners. Rogan has said he began experimenting with BPC-157 to treat elbow tendinitis caused by weightlifting and martial arts training, noting that after beginning the injections, the pain was gone in two weeks.
Peptides’ concerning second life
Peptides are short chains of amino acids that function throughout the body as signaling molecules. Many naturally occurring hormones, including insulin and GLP-1, are peptides. Because they can bind to specific biological receptors, peptide molecules have long been attractive targets for pharmaceutical research and development teams. During the past two decades, dozens of peptide-based drugs have received FDA approval for conditions ranging from diabetes and osteoporosis to cancer and autoimmune disease.
But outside the pharmaceutical pipeline, peptides have developed a second life within the wellness and biohacking communities.
In addition to BPC-157, online forums and fitness influencers routinely discuss compounds such as TB-500, which is marketed for muscle recovery, and CJC-1295 and Ipamorelin, peptides believed to stimulate growth hormone production. Other compounds such as Semax and Selank — neuropeptides originally studied in Eastern Europe — are often promoted online for cognitive performance. Sermorelin, a peptide that acts as a growth hormone-releasing hormone analogue, has also become popular in some anti-aging clinics and is frequently marketed to men to aid in athletic recovery, sexual performance and improved sleep quality.
Most of these compounds remain poorly studied in humans, but that hasn’t dampened demand, which is driven in part by companies selling peptides labeled as “research chemicals.”
The products are technically marketed for laboratory use rather than human consumption, but regulators say the distinction is often largely theoretical. Several companies have become prominent suppliers in the space, including SwissChems, Prime Peptides and Xcel Peptides. Another well-known vendor, Peptide Sciences, sold dozens of compounds online before shutting down operations earlier this year amid increasing regulatory scrutiny. The products are typically sold as freeze-dried powders that buyers reconstitute into injectable solutions.
For consumers seeking more structured guidance, a parallel ecosystem of longevity clinics and telehealth providers has emerged offering supervised peptide therapy programs. These regimens often involve multiple compounds administered in customized combinations and can cost patients several thousand dollars per year.
Clinics like Chill Cryotherapy in Westfield, NJ, offer a veritable bazaar of health and health-adjacent services ranging from teeth whitening and infrared saunas to shockwave therapy, hyperbaric oxygen therapy and peptide injections.
Ongoing federal crackdown
Federal regulators have grown increasingly concerned that enthusiasm for peptides has outpaced the underlying science. In December 2024, the FDA issued warning letters to several companies selling peptide products online, citing compounds such as retatrutide along with semaglutide and tirzepatide being marketed under “research use only” disclaimers while appearing to target consumers seeking weight-loss or performance benefits.
And more recently, the FDA issued a large batch of warning letters targeting 30 telehealth companies for how compounded GLP-1s were being sold.
Oversight remains difficult as many vendors operate internationally, and quality control is a major concern. Independent testing of some products has identified discrepancies between labeled and actual contents, including contamination or inaccurate dosages.
For pharmaceutical companies and healthcare marketers, the rise of peptides reflects a broader shift in how medical innovation moves through the marketplace. Consumers increasingly learn about experimental therapies through podcasts and social media long before those therapies appear in clinical practice.
While some peptides currently circulating in the wellness marketplace may eventually become validated therapies through clinical trials — such as retatrutide, which is currently in late-stage trials and likely to receive FDA approval — others may disappear as scientific scrutiny catches up with the hype. The peptide boom illustrates how quickly emerging biomedical technologies can migrate from the laboratory into consumer culture — often long before regulators or clinical evidence can keep pace.